Ventures Vii Lpcmea Venture... Net Worth

The estimated Net Worth of Ventures Vii Lpcmea Venture... is at least $12.4 Million dollars as of 30 January 2015. Ventures Venture owns over 170,000 units of Ardelyx Inc stock worth over $482,700 and over the last 10 years Ventures sold ARDX stock worth over $11,927,900.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ventures Venture ARDX stock SEC Form 4 insiders trading

Ventures has made over 3 trades of the Ardelyx Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Ventures sold 170,000 units of ARDX stock worth $4,652,900 on 30 January 2015.

The largest trade Ventures's ever made was buying 316,826 units of Ardelyx Inc stock on 24 June 2014 worth over $4,435,564. On average, Ventures trades about 131,138 units every 37 days since 2014. As of 30 January 2015 Ventures still owns at least 80,990 units of Ardelyx Inc stock.

You can see the complete history of Ventures Venture stock trades at the bottom of the page.

Insiders trading at Ardelyx Inc

Over the last 10 years, insiders at Ardelyx Inc have traded over $37,312,621 worth of Ardelyx Inc stock and bought 85,247,838 units worth $820,614,871 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, Ardelyx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $1,784,764. The most recent stock trade was executed by Michael Raab on 27 August 2024, trading 7,500 units of ARDX stock currently worth $46,650.

What does Ardelyx Inc do?

ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.

Complete history of Ventures Venture stock trades at Ardelyx Inc

Ardelyx Inc executives and stock owners

Ardelyx Inc executives and other stock owners filed with the SEC include:

• Michael Raab,
  President, Chief Executive Officer, Director
• Michael G. Raab,
  Pres, CEO & Director
• David Rosenbaum,
  Chief Development Officer
• Elizabeth Grammer,
  Chief Legal and Administrative Officer
• Susan Rodriguez,
  Chief Commercial Officer
• Justin A. Renz CPA, MST, M.S.T., MBA,
  CFO & Chief Accounting Officer
• Geoffrey Block,
  Independent Director
• David Mott,
  Independent Chairman of the Board
• Richard Rodgers,
  Independent Director
• Gordon Ringold,
  Independent Director
• William Bertrand,
  Independent Director
• Jan Lundberg,
  Independent Director
• Robert Bazemore,
  Independent Director
• Onaiza Cadoret-Manier,
  Independent Director
• Susan Rodriguez,
  Chief Commercial Officer
• Justin Renz,
  Chief Accounting and Principal Financial Officer
• Dr. Laura A. Williams M.D., M.P.H.,
  Chief Medical Officer
• Dan Pavicich,
  Sr. Director of Market Devel.
• David P. Rosenbaum,
  Chief Devel. Officer
• Elizabeth A. Grammer,
  Chief Legal & Admin. Officer and Sec.
• Karen Harrigan,
  Sr. Director Market Devel.
• Robert C. Blanks,
  Chief Regulatory Affairs & Quality Assurance Officer
• Sarah O'Brien,
  Chief People Officer
• Kimia Keshtbod,
  Mang. of Corp. Communications & Investor Relations
• Jeffrey W. Jacobs,
  Chief Scientific Officer
• Peter W. Sonsini,
  10% owner
• Jon Sakoda,
  10% owner
• Patrick J Kerins,
  10% owner
• 15 Gp, Llc Nea,
  10% owner
• Jeremy S Caldwell,
  EVP, Chief Scientific Officer
• Mark Kaufmann,
  Chief Financial Officer
• Harry R Weller,
  10% owner
• Ravi Viswanathan,
  10% owner
• Krishna Kittu Kolluri,
  10% owner
• Peter J Barris,
  10% owner
• Reginald Seeto,
  Chief Operating Officer
• Scott D Sandell,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Enterprise Associates 12, L...,
  
• Annalisa Jenkins,
  Director
• Paul Korner,
  EVP, Chief Medical Officer
• Joshua Makower,
  10% owner
• Forest Baskett,
  10% owner
• M James Barrett,
  10% owner
• Eric Duane Foster,
  Chief Commercial Officer
• Enterprise Associates 12, L...,
  10% owner
• Partners 12, Limited Partne...,
  
• Mohamad Makhzoumi,
  10% owner
• Muna Bhanji,
  Director
• Mike Kelliher,
  See Remarks
• Narani Arasaratnam,
  VP, Corporate Controller
• Ventures Vii Lpcmea Venture...,
  
• Peter G Schultz,
  Director
• Ryan D Drant,
  10% owner
• George Jue,
  VP, Operations & Facilities
• Partners 12, Limited Partne...,
  
• Jeffrey W Jacobs,
  Chief Scientific Officer
• Robert Ora Felsch,
  See Remarks
• Robert Blanks,
  See Remarks
• Laura A Williams,
  Chief Medical Officer